Pfizer to Acquire CovX to Bolster Biologics Pipeline

Pfizer reports that it has agreed to buy CovX to enhance its biotherapeutics portfolio. The acquisition gives Pfizer three new early-stage compounds and a technology platform.
Genetic Engineering & biotechnology News